Insulin resistance and depressed cardiac G6PD activity induced by glucocorticoid exposure during pregnancy are attenuated by maternal estrogen-progestin therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science B.V Country of Publication: Netherlands NLM ID: 9612020 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7077 (Electronic) Linking ISSN: 13826689 NLM ISO Abbreviation: Environ Toxicol Pharmacol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam : Elsevier Science B.V., c1996-
    • Subject Terms:
      Insulin Resistance*; Contraceptives, Oral, Combined/*pharmacology ; Estrogens/*pharmacology ; Ethinyl Estradiol/*pharmacology ; Glucocorticoids/*pharmacology ; Glucosephosphate Dehydrogenase/*metabolism ; Levonorgestrel/*pharmacology ; Myocardium/*enzymology ; Progestins/*pharmacology; Animals ; Drug Combinations ; Female ; Maternal-Fetal Exchange ; Pregnancy ; Rats, Wistar
    • Abstract:
      This study aimed to investigate the effects of maternal combined oral contraceptive (COC) on dams that were exposed to late gestational glucocorticoids (GC). Twenty-four pregnant female rats were randomly allotted into 4 groups of 6 dams each. Dams received COC (combination of 1.0 μg ethinylestradiol and 5.0 μg levonorgestrel p.o.) between 3rd and 11 th week after delivery with or without prior exposure to GC (dexamethasone; 0.2 mg/kg p.o.) that was administered between gestational days 14-19. Data showed that late-gestational GC exposure led to insulin resistance (IR), increased cardiac adenosine deaminase (ADA), xanthine oxidase (XO), lactate, lactate dehydrogenase (LDH), and disrupted cardiac glucose-6-phosphate dehydrogenase (G6PD)-dependent antioxidant defenses. On the other hand, maternal COC treatment in dams not exposed to gestational GC led to IR, increased cardiac XO, LDH and defective cardiac G6PD-dependent antioxidant defenses. However, maternal COC with prior gestational GC exposure led to attenuated IR, cardiac ADA, UA, LDH, and improved cardiac G6PD-dependent antioxidant defenses but worsened cardiac triglyceride (TG) accumulation when compared with dam with gestational GC exposure without maternal COC. Taken together, the findings of this study provide evidence that maternal COC treatment improves late gestational GC-programmed effects. This is however accompanied with enhanced cardiac TG accumulation.
      (Copyright © 2020 Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: G6PD-dependent; anti-oxidants; cardiac triglyceride; insulin resistance; maternal oral contraceptive; uric acid
    • Accession Number:
      0 (Contraceptives, Oral, Combined)
      0 (Drug Combinations)
      0 (Estrogens)
      0 (Glucocorticoids)
      0 (Progestins)
      0 (ethinyl estradiol, levonorgestrel drug combination)
      423D2T571U (Ethinyl Estradiol)
      5W7SIA7YZW (Levonorgestrel)
      EC 1.1.1.49 (Glucosephosphate Dehydrogenase)
    • Publication Date:
      Date Created: 20200604 Date Completed: 20210204 Latest Revision: 20210204
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.etap.2020.103423
    • Accession Number:
      32492534